LENZ Therapeutics (LENZ) has reported its Q1 2026 financial performance, aligning with previously communicated expectations. The company generated $1.9 million in net revenue for the quarter, which included $1.7 million from specific revenue streams, as detailed in its recent earnings call insights.
President, CEO, Secretary & Director Evert Schimmelpennink affirmed the company’s steady progress, stating, “In Q1, our performance was consistent with the expectations we outlined on our last call.” During this period, LENZ Therapeutics also delivered approximately 25,000 paid and filled prescriptions, underscoring its operational output.
Strategic Sales Force Expansion
Looking ahead, LENZ has outlined an ambitious strategic initiative to significantly expand its market reach. The company aims to grow its sales force to engage 15,000 eye care professionals by the close of the current quarter. This expansion is part of broader VIZZ adoption actions rolling out, signaling a focused effort to deepen penetration within the professional eye care market.
The consistent Q1 performance, coupled with aggressive sales force expansion plans, positions LENZ Therapeutics to capitalize on its market strategy and drive further adoption of its offerings among eye care professionals.
